Adjuvant daily therapy with L-arginine 2,500 mg and tadalafil 5 mg increases efficacy and duration of benefits of low-intensity extracorporeal shock wave therapy for erectile dysfunction: A prospective, randomized, single-blinded study with 1-year follow

다국어 초록 (Multilingual Abstract)

Purpose: To investigate a therapeutic protocol for erectile dysfunction (ED) based on the combination of low-intensity extracorporeal shock wave therapy (Li-ESWT), tadalafil, and L-arginine.
Materials and Methods: Recruited patients completed the International Index of Erectile Function erectile function domain (IIEF-EF) and the Erection Hardness Score (EHS) questionnaires at baseline and were randomly assigned in two groups: A (treatment group) and B (control group). Men in both groups received six weekly applications of Li-ESWT. Group A was prescribed adjuvant oral therapy with tadalafil 5 mg and L-arginine 2,500 mg. Follow-up visits were scheduled 1, 6, and 12 months after the last Li-ESWT application. At each follow-up visit, the IIEF-EF and EHS questionnaires were administered again. The main outcome measures were the changes from baseline to every follow-up visit in IIEF-EF and EHS scores.
Results: The mean IIEF-EF score in group A was 16.0±4.0, 24.8±3.4, 23.3±4.6, and 21.6±5.5 at baseline, 1, 6, and 12 months of follow-up, respectively, whereas in group B the mean IIEF-EF score was 16.5±4.1, 22.7±4.2, 21.5±4.5, and 19.5±4.9, respectively. We reported an increase in the mean EHS score in group A from 2.07±0.72 at baseline to 3.39±0.59, 3.17±0.67, and 2.98±0.72 at 1, 6, and 12 months, respectively, and in group B from 2.12±0.80 at baseline to 3.07±0.78 and 2.95±0.76 at 1 and 6 months, respectively.
Conclusions: Adjuvant daily therapy with L-arginine 2,500 mg and tadalafil 5 mg was safe and effective in increasing the efficacy and the duration of benefits of Li-ESWT.

참고문헌 (Reference)

• 1 Mulhall JP, "Validation of the erection hardness score" 4 : 1626-1634, 2007
• 2 Bechara A, "Twelve-month efficacy and safety of low-intensity shockwave therapy for erectile dysfunction in patients who do not respond to phosphodiesterase type 5 inhibitors" 4 : e225-e232, 2016
• 3 Gallo L, "The daily therapy with L-Arginine 2, 500 mg and tadalafil 5 mg in combination and in monotherapy for the treatment of erectile dysfunction : a prospective, randomized multicentre study" 8 : 178-185, 2020
• 4 Sokolakis I, "The basic science behind low-intensity extracorporeal shockwave therapy for erectile dysfunction : a systematic scoping review of pre-clinical studies" 16 : 168-194, 2019
• 5 Gallo L, "Ten-year experience with multimodal treatment for acute phase Peyronie's disease: a real life clinical report" 43 : 182-189, 2019
• 6 Aversa A, "Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction : a pilot study" 19 : 200-207, 2007
• 7 Levine LA, "Penile prosthesis surgery : current recommendations from the International Consultation on Sexual Medicine" 13 : 489-518, 2016
• 8 Rosen RC, "Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale" 60 : 1010-1016, 2011
• 9 Kalyvianakis D, "Low-intensity shockwave therapy improves hemodynamic parameters in patients with vasculogenic erectile dysfunction : a triplex ultrasonographybased sham-controlled trial" 14 : 891-897, 2017
• 10 Tsai CC, "Low-intensity extracorporeal shockwave therapy can improve erectile function in patients who failed to respond to phosphodiesterase type 5 inhibitors" 11 : 1781-1790, 2017
• 11 Palmieri A, "Low intensity shockwave therapy in combination with phosphodiesterase-5 inhibitors is an effective and safe treatment option in patients with vasculogenic ED who are PDE5i non-responders: a multicenter single-arm clinical trial" 33 : 634-640, 2021
• 12 Kitrey ND, "Low intensity shock wave treatment for erectile dysfunction-how long does the effect last?" 200 : 167-170, 2018
• 13 Srini VS, "Low intensity extracorporeal shockwave therapy for erectile dysfunction : a study in an Indian population" 22 : 7614-7622, 2015
• 14 Belew D, "Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction : a review" 3 : 11-23, 2015
• 15 Ayala HAC, "Impact on the quality of erections after completing a low-intensity extracorporeal shock wave treatment cycle on a group of 710 patients" 2017 : 1843687-, 2017
• 16 Chung E, "Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: an Australian first open-label single-arm prospective clinical trial" 115 (115): 46-49, 2015
• 17 Angulo JC, "Efficacy of low-intensity shock wave therapy for erectile dysfunction : a systematic review and meta-analysis" 41 : 479-490, 2017
• 18 El-Wakeel LM, "Efficacy and tolerability of sildenafil/l-arginine combination relative to sildenafil alone in patients with organic erectile dysfunction" 8 : 143-147, 2020
• 19 Verze P, "Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction : a matched-pair comparison study" 22 : 379-382, 2020
• 20 Fojecki GL, "Effect of linear low-intensity extracorporeal shockwave therapy for erectile dysfunction12-month follow-up of a randomized, double-blinded, shamcontrolled study" 6 : 1-7, 2018
• 21 Porst H, "Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction" 7 : 3487-3494, 2010
• 22 Cappelleri JC, "Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function" 54 : 346-351, 1999
• 23 El Taieb M, "Daily oral l-arginine plus tadalafil in diabetic patients with erectile dysfunction : a double-blinded, randomized, controlled clinical trial" 16 : 1390-1397, 2019
• 24 Yuan J, "Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction : a systematic review and network meta-analysis" 63 : 902-912, 2013
• 25 Dhir RR, "Combination therapy for erectile dysfunction : an update review" 13 : 382-390, 2011
• 26 Sokolakis I, "Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction : a systematic review and meta-analysis of randomised controlled trials" 31 : 177-194, 2019
• 27 Olsen AB, "Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebocontrolled study" 49 : 329-333, 2015
• 28 Corona G, "Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS)" 7 (7): 1362-1380, 2010
• 29 Salonia A, "2020 EAU guidelines on sexual and reproductive health [Internet]"